Eli Lilly licenses Hanmi's GLP-2 asset for $75 million upfront
read at Endpoints ↗DealNeutral
Eli Lilly has signed a licensing agreement with South Korean biotech Hanmi to acquire rights to a GLP-2 drug candidate, paying an upfront cash payment of $75 million.
The deal marks Lilly's entry into the GLP-2 therapeutic space, expanding beyond its highly profitable GLP-1 portfolio that has driven billions in sales.
In addition to the GLP-2 license, Lilly also entered a discovery collaboration with China's Haisco, broadening its pipeline development partnerships in Asia.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfront”
read at Endpoints ↗89 words · retrieved Jun 2
comments(0)
5-min edit window · permanent after that